Temporal trends in ischemic stroke and anticoagulation therapy among Medicare beneficiaries with non-valvular atrial fibrillation with and without diabetes mellitus, 1992-2010

Gautam R. Shroff, MBBS¹, Craig A. Solid, PhD², Charles A. Herzog, MD¹,²
¹Hennepin County Medical Center/University of Minnesota, Minneapolis, MN, ²Chronic Disease Research Group, Minneapolis, MN

Introduction
• There has been a decline in ischemic stroke rates in the Medicare population, coincident with increasing rates of anticoagulation. ¹,²
• Patients with diabetes mellitus (DM) and atrial fibrillation (AF) are at increased risk of ischemic stroke; but evidence regarding reduction in ischemic stroke with warfarin use in the literature is limited.
• We evaluated temporal trends in ischemic stroke and warfarin use among the US Medicare population with and without DM.

Methods
• One-year cohorts of patients with Medicare as primary payer, 1992-2010, were created using the Medicare 5% sample.

Methods (cont’d)
• ICD-9-CM codes were used to identify AF, ischemic and hemorrhagic stroke and comorbidities
• ≥3 consecutive prothrombin-time claims were used to identify warfarin use. ¹,²
• Patients with valvular heart disease and ESRD were excluded.

Results
Demographic characteristics between 1992 (n=40255) and 2010 (n=80314) respectively were (proportions):
• age 65-74 years (37%, 32%)
• age ≥ 85 years (20%, 25%)
• white (94%, 93%)
• hypertension (46%, 80%)
• DM (20%, 32%)
• chronic kidney disease (5%, 18%)

Among Medicare AF patients with DM:
• Ischemic stroke rates decreased by 71% (1992, 2010) from 65/1000 to 19/1000 patient-years
• Warfarin utilization increased from 28% to 62% respectively (Figure 1A).

Among Medicare AF patients without DM:
• Ischemic stroke rates decreased by 68% from 44 to 14/1000 patient-years
• Warfarin use increased 26% to 59% respectively (Figure 1B).

About 38% Medicare AF pts with DM did not receive anticoagulation in 2010.

Conclusions
• Medicare patients with and without DM had a similar reduction in ischemic stroke rates; and similar increase in warfarin utilization over the study period.
• Ischemic strokes rates among patients with DM were consistently higher than non-DM patients; thus validating the inclusion of DM in risk calculators.
• A significant proportion of Medicare pts with DM did not receive anticoagulation with warfarin for AF in 2010; this population deserves future attention.

References